Cortexolone 17α‐propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double‐blind comparative study vs. placebo and tretinoin 0·05% cream

@article{Trifu2011Cortexolone11,
  title={Cortexolone 17α‐propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double‐blind comparative study vs. placebo and tretinoin 0·05% cream},
  author={V. Trifu and G. Tiplica and E. Naumescu and L. Zalupca and L. Moro and G. Celasco},
  journal={British Journal of Dermatology},
  year={2011},
  volume={165}
}
  • V. Trifu, G. Tiplica, +3 authors G. Celasco
  • Published 2011
  • Medicine
  • British Journal of Dermatology
  • Background  Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17α‐propionate (CB‐03‐01; Cosmo S.p.A, Lainate, Italy) is a new potent topical antiandrogen potentially useful in acne vulgaris. 
    New investigational drugs for androgenetic alopecia
    • 31
    Emerging drugs for the treatment of acne
    • 25
    A review of diagnosis and treatment of acne in adult female patients☆☆☆
    • 28
    Anti-acne drugs in phase 1 and 2 clinical trials
    • 18

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 18 REFERENCES
    Rook's Textbook of Dermatology
    • 1,726
    • PDF